Format

Send to

Choose Destination
Diabetes Metab Res Rev. 2018 Dec 4:e3109. doi: 10.1002/dmrr.3109. [Epub ahead of print]

Pharmacogenetics of Type 2 Diabetes Mellitus, the route toward tailored medicine.

Author information

1
Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global epidemic. In order to achieve optimal glucose control it is often necessary to rely on combination therapy of multiple drugs or insulin, because uncontrolled glucose levels result in T2DM progression and enhanced risk of complications and mortality. Several anti-hyperglycemic agents have been developed over time, and T2DM pharmacotherapy should be prescribed based on suitability for the individual patient's characteristics. Pharmacogenetics is the branch of genetics that investigates how our genome influences individual responses to drugs, therapeutic outcomes, and incidence of adverse effects. In this review we evaluated the pharmacogenetic evidences currently available in the literature and we identified the top informative genetic variants associated with response to the most common anti-diabetic drugs: metformin, DPP-4 inhibitors/GLP1R agonists, thiazolidinediones and sulfonylureas/meglitinides. Overall we found 40 polymorphisms for each drug class in a total of 71 loci, and we examined the possibility of encouraging genetic screening of these variants/loci in order to critically implement decision making about the therapeutic approach through precision medicine strategies. It is possible then to anticipate that when the clinical practice will take advantage of the genetic information of the diabetic patients, this will provide a useful resource for the prevention of T2DM progression, enabling the identification of the precise drug that is most likely to be effective and safe for each patient, and the reduction of the economic impact on a global scale.

KEYWORDS:

T2DM; pharmacogenetics; precision medicine; translational medicine; type 2 diabetes mellitus

PMID:
30515958
DOI:
10.1002/dmrr.3109

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center